Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JAK2 inhibitor G5-7 (JAK2 inhibitor G5-7) 是具有口服活性的JAK2变构抑制剂,可通过结合到 JAK2,选择性的抑制JAK2介导的 EGFR 和 STAT3 的磷酸化和激活。它诱导细胞周阻滞和诱导凋亡、具有抗血管生成活性。它有用于胶质瘤研究的潜能。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 472 | 现货 | ||
5 mg | ¥ 1,330 | 现货 | ||
10 mg | ¥ 1,930 | 现货 | ||
25 mg | ¥ 3,570 | 现货 | ||
50 mg | ¥ 4,970 | 现货 | ||
100 mg | ¥ 6,880 | 现货 | ||
500 mg | ¥ 13,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,460 | 现货 |
产品描述 | JAK2 inhibitor G5-7 (JAK2 inhibitor G5-7) is an orally active JAK2 inhibitor, selectively inhibits JAK2–mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 has the potential for glioma study |
体外活性 | G5-7 that selectively inhibited Janus kinase 2 (JAK2)-mediated phosphorylation and activation of EGFR and STAT3 (signal transducer and activator of transcription 3) by binding to JAK2, thereby decreasing the activity of downstream signaling by mTOR (mammalian target of rapamycin) and inducing cell cycle arrest.?G5-7 inhibited the proliferation of PTEN-deficient glioblastoma cell lines harboring a constitutively active variant of EGFR (U87MG/EGFRvIII) and human glioblastoma explant neurosphere cultures, but the drug only weakly inhibited the proliferation of either glioblastoma cell lines that were wild type for EGFR and stably transfected with PTEN (U87MG/PTEN) or normal neural progenitor cells and astrocytes.?Additionally, G5-7 reduced vascular endothelial growth factor (VEGF) secretion and endothelial cell migration and induced apoptosis in glioblastoma xenografts, thereby suppressing glioblastoma growth in vivo.?Furthermore, G5-7 was more potent than EGFR or JAK2 inhibitors that interfere with either ligand or adenosine 5'-triphosphate (ATP) binding at impeding glioblastoma cell proliferation. |
别名 | JAK2 inhibitor G5-7 |
分子量 | 383.39 |
分子式 | C22H19F2NO3 |
CAS No. | 939681-36-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22.5 mg/mL (58.69 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6083 mL | 13.0416 mL | 26.0831 mL | 65.2078 mL |
5 mM | 0.5217 mL | 2.6083 mL | 5.2166 mL | 13.0416 mL | |
10 mM | 0.2608 mL | 1.3042 mL | 2.6083 mL | 6.5208 mL | |
20 mM | 0.1304 mL | 0.6521 mL | 1.3042 mL | 3.2604 mL | |
50 mM | 0.0522 mL | 0.2608 mL | 0.5217 mL | 1.3042 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
G5-7 939681-36-4 Angiogenesis Apoptosis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK antiangiogenic inhibit Glioma G-5-7 cycle G5 7 phase G57 STAT3 cell Inhibitor JAK2 inhibitor G5-7 EGFR Janus kinase mTOR inhibitor